Introduction {#S1}
============

Obesity, defined as the excessive accumulation of body fat, is considered a global public health problem in children and adolescents. According to reports by the World Health Organization in 2016, up to 650 million adults suffer from obesity worldwide. In the past, obesity was only a common problem in developed countries, while today, it also occurs in developing countries ([@B69]). Increased body mass index (BMI) is considered a major risk factor for diseases associated with obesity, such as metabolic syndrome, cardiovascular disease, type II diabetes, and cancer ([@B22]; [@B60]; [@B40]).

Obesity is generally a multifactorial phenomenon. The gut microbiota is one of the factors, which has been recently considered in obesity ([@B10]). The gut microbiota is defined as trillions of microbes, which colonize in the gastrointestinal tract, and play a crucial role in human health ([@B72]). Changes in the intestinal microbiota occur instantly after dietary changes, affecting numerous molecular pathways ([@B18]). Evidence shows that a high-fat diet (HFD) can cause an increase in the adipocyte size and improve weight gain. It can also result in the local inflammation of adipose tissues, which play an effective role in obesity through modulation of host metabolism by secretion of various hormones and cytokines ([@B66]; [@B31]; [@B54]; [@B64]).

Obesity-induced adipose tissue dysfunction causes an increase in the level of free fatty acids and inflammatory cytokines and promotes hypertrophy and hyperplasia. In addition, HFD is associated with dysbiosis, mucosal barrier disruption, lipopolysaccharide (LPS) diffusion, and metabolic endotoxemia ([@B12]; [@B24]). On the other hand, accumulating evidence shows that probiotics can ameliorate obesity by improving the gut microbiota disruption, strengthening the gut barrier, alleviating inflammation, reducing body weight and fat storage, and inducing energy balance by affecting various mechanisms ([@B21], [@B20]; [@B51]; [@B64]).

*Akkermansia muciniphila* is a beneficial gastrointestinal microbiota, which was recently introduced as a next-generation probiotic ([@B14]). This mucin-degrading bacterium can influence the regulation of energy homeostasis and weight control ([@B24]; [@B51]) and promote the intestinal barrier function ([@B24]; [@B56]; [@B49]). Reduction in the abundance of this bacterium, as reported in multiple studies, indicates its pivotal role in the prevention of obesity ([@B24]; [@B58]; [@B17]). It is known that the intestinal microbiota can modulate different signaling pathways by secreting extracellular vesicles (EVs). According to recent studies, not only EVs seem to be capable of passing the mucus and internalizing the epithelium, but they can also access the immune cells in the lamina propria as well as play a crucial role in the maintenance of immune and gut homeostasis by upregulation of tight junction proteins and modulation of immune responses ([@B42]; [@B25]; [@B2]; [@B8]). Animal studies show that *A. muciniphila*-derived EVs were able to improve the intestinal barrier by increasing tight junctions ([@B15]) and ameliorating inflammation caused by colitis ([@B37]).

Involvement of the gut microbiota in weight changes is considered an important issue in obesity; therefore, it is essential to determine the association of microbiota with weight loss using probiotics. In the present study, nine HFD microarray datasets were selected. A meta-analysis of obesity-related genes was performed after batch effect removal. The anti-obesity and anti-inflammatory effects of *A. muciniphila* and its EVs were examined in epididymal adipose tissues (EAT). Also, colonic immunomodulatory properties of this bacterium and its EVs were assessed by measuring the concentration of cytokines in colon carcinoma cells (Caco-2) and evaluating the expression of cytokines and TLR-2/4 receptors in the colon of mice. Finally, the effects of *A. muciniphila* and its EVs on the intestinal barrier integrity, fat storage, and energy homeostasis were examined.

Materials and Methods {#S2}
=====================

Preparation of *A. muciniphila* {#S2.SS1}
-------------------------------

*Akkermansia muciniphila MucT* (ATCC BAA-835) was obtained from the DSMZ institute (German collection of microorganisms and cell cultures). The bacterium was cultured in a basal mucin-based medium under the anaerobic conditions at 37°C for 3--7 days ([@B19]). After growth, the bacterium was inoculated into brain heart infusion (BHI) Broth (Quelab, Canada) supplemented with 0.5% mucin (Sigma-Aldrich) with mild shaking (150 rpm) under the abovementioned conditions for 48 h until an OD~600~ of 1 was reached. Bacterial pellets were removed by centrifugation (11,000 *g* for 20 min) and washed twice with an anaerobic PBS. The remaining supernatant was used for EVs extraction. *A*. *muciniphila* suspension was immediately placed on ice and then used for cell culture treatment and oral administration in mice.

EVs Isolation {#S2.SS2}
-------------

After filtering the supernatant, EVs were extracted with ultracentrifuge at 200,000 *g* for 2 h at 4°C as previously described ([@B37]). The pellets were resuspended in PBS and stored at --80°C. Scanning electron microscopy (SEM) was used to identify the morphology of its EVs and then the pattern of protein sample was assessed by SDS-PAGE. The presence of LPS in EVs was measured by LAL Chromogenic Endotoxin Quantitation Kit (Thermo Fisher Scientific, United States) according to the manufacturer's instructions.

Animal Experiments {#S2.SS3}
------------------

Thirty male C57BL/6 mice were purchased from Pasteur Institute of Karaj (Iran), maintained in equal conditions (12 h light, 22--23°C, and 40% humidity) with *ad libitum* access to food and autoclaved water. After 1 week of acclimation with standard normal diet (ND) (A03, safe diet, France), 8-week-old mice were randomly divided into two groups, and each group was divided into three subgroups as follows:

The first group was fed HFD (260 HF 60% energy from butter, safe diet, France) for 3 months. After weight gain, treatment for 5 weeks along with HFD ([Figure 1A](#F1){ref-type="fig"}):

![Morphologic characterization of EVs and impact of *Akkermansia muciniphila* and its EV administration on body and adipose weight, food intake, and blood parameters in both ND- and HFD-fed mice after 5 weeks (*n* = 5 for each group). **(A)** Illustration showing obesity induction and amelioration after treatment. **(B)** Scanning electron micrograph image of *A. muciniphila*-derived EVs. **(C)** Body weight gain per mouse. **(D)** Average daily food intake. **(E)** Epidydimal adipose weight (EAT). **(F)** Histopathology image. Scale bar is 50 μm. **(G)** Total cholesterol levels. **(H)** Triglyceride levels and **(I)** glucose levels. ^∗^*P* \< 0.05 and ^∗∗^*P* \< 0.01 were considered statistically significant, respectively. ND, normal diet + PBS; NA.m, normal diet + *A. muciniphila* (10^9^ CFU); NEV, normal diet + EVs (10 μg protein); HFD, high-fat diet + PBS; HA.m, high-fat diet + *A. muciniphila* (10^9^ CFU); HEV, high-fat diet + EVs (10 μg protein).](fmicb-10-02155-g001){#F1}

1.  HFD + 200 μl PBS (HPBS)

2.  HFD + 10^9^ CFU/200 μl alive *A. muciniphila* (HA.m)

3.  HFD + 10 μg protein/200 μl EVs (HEV)

The second group was fed normal diet (A03) under the above conditions ([Figure 1A](#F1){ref-type="fig"}):

1.  ND + 200 μl PBS (NPBS)

2.  ND + 10^9^ CFU/200 μl alive *A. muciniphila* (NA.m)

3.  ND + 10 μg protein/200 μl EVs (NEV)

Body weight, average food, and water intake were measured once a week. Note that at the end of the experiment, HFD-fed mice exhibiting aggressive behavior and resistant to obesity were excluded from our study. Before and after oral gavage, blood was collected *via* tail vein and stored at --80°C until biochemical analysis. At the end of treatment, all of the mice were sacrificed by cervical dislocation, and EAT and colon samples were snap frozen with liquid nitrogen and stored at --80°C. Moreover, the tissues are saved for histopathology analysis. We followed the institute guidelines regarding the care and use of laboratory animals. The study protocol was approved by the Animal Experiment Committee of Pasteur Institute of Iran.

Computation of Selected Gene Expression {#S2.SS4}
---------------------------------------

Gene expression datasets were downloaded from the National Center for Biotechnology Information gene expression omnibus (GEO). Our inclusion criteria to obtain relevant datasets were as follows: (a) studies qualifying as HFD experiments; (b) mouse samples for the experimental setups; (c) the number of samples for each group ND and HFD must be more than one; (d) using epididymal adipose tissue; and (e) survey the expression of all selected genes. A total of nine datasets ([Table 1](#T1){ref-type="table"}) that qualified for our study were obtained.

###### 

List of datasets used in meta-analysis.

  **GEO series ID**   **GEO platform ID**                                                                           **No. of ND sample**   **No. of HFD sample**   **HFD (% of energy from fat)**   **Sample**   **Submission date**
  ------------------- --------------------------------------------------------------------------------------------- ---------------------- ----------------------- -------------------------------- ------------ ---------------------
  GSE65557            GPL6246 \[(MoGene-1_0-st) Affymetrix Mouse Gene 1.0 ST Array (transcript (gene) version)\]    3                      3                       60%                              EAT          2015
  GSE44653                                                                                                          3                      3                       42%                              EAT          2013
  GSE28440                                                                                                          3                      3                       45%                              EAT          2011
  GSE100388           GPL1261 \[(Mouse430_2) Affymetrix Mouse Genome 430 2.0 Array\]                                5                      5                       39.9%                            EAT          2017
  GSE71367                                                                                                          9                      9                       39.9%                            EAT          2015
  GSE19954                                                                                                          2                      2                       30%                              EAT          2010
  GSE36033            GPL11533 \[(MoGene-1_1-st) Affymetrix Mouse Gene 1.1 ST Array (transcript (gene) version)\]   3                      3                       60%                              EAT          2012
  GSE39549            GPL6887 (Illumina MouseWG-6 v2.0 expression beadchip)                                         3                      3                       39.2%                            EAT          2012

All analyses were undertaken using the R (version 3.5.2) statistical computing environment and Bioconductor (version 3.9). The individual datasets were normalized followed by log2 transformation before meta-analysis. We mapped the probeset identifiers in each gene expression dataset into their corresponding gene symbol using an annotation table available with the respective data at GEO. Multiple probeset identifiers can be mapped to the same gene symbol, and we removed the duplicity by using the means factor of respective entry. We performed data merging to correct for batch effects using the ComBat function of the SVA package ([@B43]). Then, we surveyed the expression of all selected genes across the nine datasets.

Biochemical Parameters Analysis {#S2.SS5}
-------------------------------

After blood collection, fasting blood glucose (Glc), total cholesterol (TC), and triglyceride (TG) concentrations were measured in the plasma using a commercial kit (Bioclin-Quibasa, Belo Horizonte, MG, Brazil).

Histological Evaluation {#S2.SS6}
-----------------------

At first, colon and EAT were immersed in 10% neutral buffered formalin, dehydrated, and embedded in paraffin. The tissue sections were stained with hematoxylin and eosin (H&E). Microscopic observation of the histological slides was performed using a light microscope ([@B23]).

Tissue RNA Isolation, cDNA Synthesis, and Real-Time PCR {#S2.SS7}
-------------------------------------------------------

Frozen colon and EAT were homogenized in 1 ml of Trizol (cat \# BS410, Bio Basic, Canada) using a Precellys 24 homogenizer, and then total RNA was extracted according to the manufacturer's instructions. For genomic DNA removal, RNA was treated with DNase I (Qiagen) and then cDNA was synthesized using PrimeScript RT Reagent Kit (Takara). Real-time PCR was performed using SYBR Premix Ex Taq II (Takara). A sequence of primers used in this study is shown in [Table 2](#T2){ref-type="table"}.

###### 

Sequence of primers used in qPCR in cell line and mice.

  **Primer name**   **Forward primer**          **Reverse primer**         **Product size (bp)**
  ----------------- --------------------------- -------------------------- -----------------------
  *m-RPL-19*        TCAGCCACAACATTCTCA          GCACCTCCAACAGTAAGT         138
  *m-TLR-2*         TCCTGCGAACTCCTATCC          CCTGGTGACATTCCAAGAC        151
  *m-TLR-4*         GCCTTTCAGGGAATTAAGCTCC      GATCAACCGATGGACGTGTAAA     114
  *m-ZO-1*          GCCGCTAAGAGCACAGCAA         TCCCCACTCTGAAAATGAGGA      134
  *m-CLDN-1*        TCTGCCACTTCTCACTTCCA        GCCTATACCCTTGCTCTCTGT      95
  *m-CLDN-2*        CAACTGGTGGGCTACATCCTA       CCCTTGGAAAAGCCAACCG        128
  *m-OCLDN*         TTGAAAGTCCACCTCCTTACAGA     CCGGATAAAAAGAGTACGCTGG     129
  *m-IL-10*         GCACTACCAAAGCCACAAG         AGTAAGAGCAGGCAGCATAG       85
  *m-TNF-*α         AACAACTACTCAGAAACACAAG      GCAGAACTCAGGAATGGA         130
  *m-ANGPTL4*       ACTGTGAGATGACTTCAGATGG      ATTGGCTTCCTCGGTTCC         174
  *m-HPRT*          TCAGTCAACGGGGGACATAAA       GGGGCTGTACTGCTTAACCAG      142
  *m-PPAR-*α        CACTTGCTCACTACTGTCCTT       GATGCTGGTATCGGCTCAA        110
  *m-PPAR-*γ        GGTGCTCCAGAAGATGACAGA       TCAGCGGGTGGGACTTTC         154
  *m-TGF-*β*1*      AATTCCTGGCGTTACCTT          TGTATTCCGTCTCCTTGG         116
  *m-IL-6*          TCCATCCAGTTGCCTTCT          TAAGCCTCCGACTTGTGAA        137
  *GAPDH*           GGAGCGAGATCCCTCCAAAAT       GGCTGTTGTCATACTTCTCATGG    197
  *TLR-2*           TTATCCAGCACACGAATACACAG     AGGCATCTGGTAGAGTCATCAA     160
  *TLR-4*           AGACCTGTCCCTGAACCCTAT       CGATGGACTTCTAAACCAGCCA     147
  *ZO-1*            CAACATACAGTGACGCTTCACA      CACTATTGACGTTTCCCCACTC     105
  *OCLDN*           AAGAGTTGACAGTCCCATGGCATAC   ATCCACAGGCGAAGTTAATGGAAG   133
  *CLDN-1*          GCATGAAGTGTATGAAGTGCTTGG    CGATTCTATTGCCATACCATGCTG   132
  *ANGPTL4*         ATGCCCAGTACGAACATTTCC       CTGAGTCAAGGGTGCTAAAGC      135

m, mice.

Cell Culture Conditions {#S2.SS8}
-----------------------

The Caco-2 (ATCC^®^ HTB-37) was cultured at 37°C in 5% CO~2~ in Dulbecco's modified eagle's medium (DMEM) (Gibco, United Kingdom), supplemented with 10% heat-inactivated fetal bovine serum (FBS, Gibco), and 1% penicillin--streptomycin (Gibco) in six-well plates (Sorfa, China). The medium was changed every 2--3 days. *Mycoplasma* spp. contamination was assessed using PCR method.

Cell Culture Treatment {#S2.SS9}
----------------------

After 21 days, Caco-2 monolayer was infected with *A. muciniphila* at multiplicity of infection (MOI) ratios of 100 (100 bacteria per cell). Besides, 10 μg of EV was used for Caco-2 treatment. An equal volume of PBS was used as a control. Hence, cell viability was checked after treatments.

RNA Extraction, cDNA Synthesis, and Quantitative Real-Time PCR {#S2.SS10}
--------------------------------------------------------------

After 24 h, total RNA was extracted from treated cells using the RNeasy Plus Mini Kit (Qiagen, United States, Cat No./ID: 74134). cDNA synthesis was performed by PrimeScript RT Reagent Kit (Takara, Japan, Cat. \# RR037A) according to the manufacturer's instruction. Real-time PCR was performed by 2X SYBR Premix Ex Taq II (Tli RNase H, Plus Takara, Japan, Cat. \#RR820L). A sequence of primers used in this study is shown in [Table 2](#T2){ref-type="table"}.

Cytokine Assay {#S2.SS11}
--------------

After 24 h post-treatment, both treated and untreated cell supernatants were collected and stored at --80°C. After thawing and prior to using, the supernatant was centrifuged for 10 min at 1000 g to remove any residual cells. The level of cytokines and chemokines (IL-1A, IL-1B, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-17A, IFN-γ, TNF-α, and GM-CSF) was measured by Human Inflammatory Cytokines Multi-Analyte ELISA Array^TM^ Kits (Qiagen, Cat. no. MEH-004A) according to the manufacturer's instructions. This assay was performed in duplicate.

Statistical Analysis {#S2.SS12}
--------------------

The ΔΔCT method was used for the relative gene expression analysis, and *GAPDH* in cell line and *RPL-19* in colon and *HPRT* in adipose tissue of mice were used as an internal control. GraphPad Prism 8.0 (GraphPad Software Inc., CA, United States) was used for cycle threshold (CT) values analysis to calculate changes in gene expression and cytokine concentration comparison. A *P* value of less than 0.05 was considered statistically significant.

Results {#S3}
=======

Morphology and Size Range of EVs {#S3.SS1}
--------------------------------

The extracted EVs from *A. muciniphila* were evaluated by SEM; the results showed a spherical shape and a range of 40 to 150 nm in size ([Figure 1B](#F1){ref-type="fig"}).

*A. muciniphila* and Its EVs Reduced Food Intake and Body and Adipose Weight Gain {#S3.SS2}
---------------------------------------------------------------------------------

High-fat diet-induced obese mice were used in this experiment to evaluate the role of *A. muciniphila* and its EVs on weight control. HFD-fed mice showed increase diet-induced body weight after 3 months. Obese mice were gavaged by *A. muciniphila-*derived EVs and showed low level of body weight gain and significant reduction in food intake ([Figures 1C,D](#F1){ref-type="fig"}). Hence, feeding obese mice with this bacterium caused body and EAT weight loss, but lower effect on body weight and adipose weight was observed compared to its EVs ([Figures 1C,E](#F1){ref-type="fig"}). Interestingly, both of them significantly influence body weight in ND mice, whereas food intake did not change significantly ([Figure 1D](#F1){ref-type="fig"}). The HFD group included the largest adipocytes compared to other groups ([Figure 1F](#F1){ref-type="fig"}). In HFD-fed mice, administration of this bacterium and EVs considerably decreased the adipocyte size while the effects of EVs were more noticeable ([Figure 1F](#F1){ref-type="fig"}). The smallest adipocytes were found in the ND group that received *A. muciniphila* and its EVs, compared to that in other groups ([Figure 1F](#F1){ref-type="fig"}). Overall, the adipocyte size and infiltration were enhanced after feeding HFD whereas administration with this bacterium and EVs reduced them ([Figure 1F](#F1){ref-type="fig"}).

The extracellular vesicles corrected HFD-induced hypercholesterolemia with significantly lower plasma TC ([Figure 1G](#F1){ref-type="fig"}). After EVs administration, TG levels did not change ([Figure 1H](#F1){ref-type="fig"}). Moreover, treatment with EVs displayed significantly lower plasma glucose in both groups ([Figure 1I](#F1){ref-type="fig"}). Obese mice treated with *A. muciniphila* displayed significantly lower plasma TG and glucose concentrations ([Figures 1H,I](#F1){ref-type="fig"}). In the normal group, the bacterium treatment elicited significantly decreasing plasma TG and glucose levels compared to the control (PBS) group ([Figures 1H,I](#F1){ref-type="fig"}).

Different Genes Involved in Inflammation and FA Oxidation Change in the Adipose Tissues of HFD-Fed Mice {#S3.SS3}
-------------------------------------------------------------------------------------------------------

After meta-analyzing, we found that the expression of these genes in EAT are closely related to obesity and were significantly differentially expressed with *P* value \< 0.05 by the Mann--Whitney method. As it is shown in the heatmap plot ([Figure 2A](#F2){ref-type="fig"}), inflammatory mediators (i.e., TNF-α and IL-6), TLR-4, and TGF-β were expressed at significantly higher levels in the obese than in the normal group (*P* value TLR4 and IL-6 = 0.0004, TNF-α and TGF-β \< 0.0001), moreover regulator genes involved in FA oxidation and inflammation were downregulated in HFD- compared to ND-fed mice (*P* value PPAR-γ = 0.01 and PPAR-α = 0.001). Principal component analysis (PCA) was applied for the selected gene between all 34 HFD and 34 ND samples from nine datasets. PCA ([Figure 2B](#F2){ref-type="fig"}) showed that the ND group (indicated by blue color) was clustered relatively from the HFD group (indicated by orange color). Since these genes showed similar and significant trends in all datasets and also play a key role in adiposity and inflammation, these genes were selected to study the effect of *A. muciniphila* and its EVs on obesity-related genes.

![Heatmap and PCA correlation show different genes involved in inflammation and FA oxidation in the epididymal adipose tissue between HFD and ND mice. **(A)** Heatmap plot revealed inflammatory genes (*TNF-*α, *IL-6*, and *TLR-4*) and *TGF-*β were expressed at significantly higher levels in the obese than in the normal group. **(B)** Regulator genes involved in FA oxidation and inflammation (*PPAR-*γ and *PPAR-*α) were downregulated in HFD- compared to ND-fed mice. PCA plot showed that the ND group was clustered relatively from the HFD group. The HFD and ND groups are indicated by orange and blue colors, respectively.](fmicb-10-02155-g002){#F2}

Treatment With *A. muciniphila* and Its EVs Was Correlated With the Regulation of Gene Expression Involved in FA Oxidation and Energy Metabolism of Adipose Tissues {#S3.SS4}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------

To investigate the effect of *A. muciniphila* and its EVs on FA oxidation and energy metabolism in mice, expression of *PPAR-*α/γ and *TGF-*β in adipose tissue was evaluated by real-time PCR. In obese mice, *A. muciniphila* influenced fatty acid oxidation and energy metabolism, accompanied by increased expression of *PPAR-*α, and *PPAR*-γ in adipose tissue ([Figures 3A,B](#F3){ref-type="fig"}). The EVs significantly induced overexpression of *PPAR-*α in EAT in obese groups in comparison to the bacterium ([Figure 3B](#F3){ref-type="fig"}). Both treatments enhanced expression of *PPAR-*α and *PPAR*-γ in normal mice, and the EV effects were more noticeable ([Figures 3A,B](#F3){ref-type="fig"}). In obese mice, a significant rise in levels of *TGF-*β expression in EAT was observed; in contrast, in normal mice being treated with the bacterium, EVs reduced this expression ([Figure 3C](#F3){ref-type="fig"}). The bacterium induced significantly more reduction in levels of *TGF-*β expression in EAT of obese and normal groups, compared to EVs ([Figure 3C](#F3){ref-type="fig"}).

![The effect of *A. muciniphila* and its EVs on mRNA expression of genes in epidydimal adipose tissue in C57bl/6 mice. Relative mRNA expression of **(A)** *PPAR*-γ, **(B)** *PPAR-*α, **(C)** *TGF-*β, **(D)** *TLR-4*, **(E)** *TNF-*α, and **(F)** *IL-6.* Data are normalized using *HPRT* as control gene. ^∗^*P* \< 0.05 and ^∗∗^*P* \< 0.01 were considered statistically significant, respectively. ND, normal diet + PBS; NA.m, normal diet + *A. muciniphila* (10^9^ CFU); NEV, normal diet + EVs (10 μg protein); HFD, high-fat diet + PBS; HA.m, high-fat diet + *A. muciniphila* (10^9^ CFU); HEV, high-fat diet + EVs (10 μg protein).](fmicb-10-02155-g003){#F3}

Adipose Inflammation Alleviated After Oral Administration of *A. muciniphila* and Its EVs in Obese Mice {#S3.SS5}
-------------------------------------------------------------------------------------------------------

Since obesity is associated with a low-grade inflammatory state in adipose tissues, the role of *A. muciniphila* and its EVs on expression of adipose inflammatory genes was assessed in HFD-induced obese mice. Administration of *A. muciniphila* reduced the mRNA expression of *TLR-4* and *IL-6* genes in EAT in both groups, but it did not affect *TNF-*α expression in obese mice, while there was an increase in this gene in normal mice ([Figures 3D--F](#F3){ref-type="fig"}). However, EVs induced more reduction in inflammatory cytokines (*TNF-*α and *IL-6*) and *TLR-4* expression in HFD mice ([Figures 3D--F](#F3){ref-type="fig"}). In normal mice, EVs had more reduction in *TNF-*α and *TLR-4* expression ([Figures 3D,E](#F3){ref-type="fig"}), compared to the bacterium.

Administration of *A. muciniphila* and Its EVs Ameliorated HFD-Induced Intestinal Barrier Dysfunction in Obese Mice {#S3.SS6}
-------------------------------------------------------------------------------------------------------------------

The colon is the first site affected by HFD, and dysbiosis induces different obesity pathways. Therefore, we investigated the effects of *A. muciniphila* and its EVs on pathology of colon tissues. Crypt depth and thickness of the mucous layer of the colon showed a considerable decrease in the HFD group, compared to that in the control group. Furthermore, mild infiltration of inflammatory cells in the lamina propria of the colon was present after HFD. On the contrary, no inflammatory reaction was present in other groups. An increase in crypt depth and mucosal thickness of colon tissue was observed in groups that received *A. muciniphila* and its EVs, compared to that in the HFD group (a). In the normal group, both administration of the bacterium and its EVs showed an increase in mucosal thickness ([Figure 4A](#F4){ref-type="fig"}). Since an increase in the intestinal mucosal permeability occurs in obesity, HFD-induced obese mice that disrupted the intestinal barrier were selected. In obese mice, the EVs significantly reduced gut barrier permeability. These observations were accompanied by upregulated tight junction expression (*ZO-1*, *OCLDN*, and *CLDN-1*) and downregulated *CLDN-2* in the colon of mice treated with EVs ([Figures 4B--E](#F4){ref-type="fig"}). There was an increase in mRNA level of tight junction in response to being treated with *A. muciniphila* in obese mice, while EVs had better effect. In normal mice, the bacterium effects were more noticeable ([Figures 4B--E](#F4){ref-type="fig"}). Also, to determine whether *A. muciniphila* and its EVs have a direct effect on the intestinal epithelial cells or indirectly play a role by making changes in the composition of gut microbiota, Caco-2 cell lines were used. In terms of cell viability, more than 98% of the cells survived after treatment with the bacterium, and its EVs (data not shown). After treatment, the bacterium and EVs strongly increased intestinal integrity by tight junction genes' upregulation in the cell line ([Figure 5A](#F5){ref-type="fig"}).

![The assessment of *A. muciniphila* and its EVs effect on obesity-related genes in the colon of HFD- and ND-fed mice. Both mice administrated to this bacterium and EVs for 5 weeks. **(A)** Histopathology image. M, tunica muscularis; S, submucosa layer. Crypt depth (arrows). Mucous thickness (arrowheads). Scale bar is 200 μm. Expression of **(B)** *ZO-1*, **(C)** *OCLDN*, **(D)** *CLDN-1*, **(E)** *CLDN-2*, **(F)** *TLR-4*, **(G)** *TLR-2*, **(H)** *TNF-*α, **(I)** *IL-10*, and **(J)** *ANGPTL4*. Data are normalized using *RPL-19* as control gene. ^∗^*P* \< 0.05 and ^∗∗^*P* \< 0.01 were considered statistically significant, respectively. ND, normal diet + PBS; NA.m, normal diet + *A. muciniphila* (10^9^ CFU); NEV, normal diet + EVs (10 μg protein); HFD, high-fat diet + PBS; HA.m, high-fat diet + *A. muciniphila* (10^9^ CFU); HEV, high fat-diet + EVs (10 μg protein).](fmicb-10-02155-g004){#F4}

![The effect of *A. muciniphila* and its EVs on the study's genes and cytokine secretion in the Caco-2 cell line. Caco-2 monolayers were treated with *A. muciniphila* (MOI~100~) and EV concentration (10 μg) for 24 h. The expression of genes: **(A)** *ZO-1, OCLDN*, and *CLDN-1*; **(B)** *TLR-2* and *TLR-4*; and **(C)** *ANGPTL4*. The levels of cytokines: **(D)** IL-6 and IL-8; **(E)** TNF-α and IL-10; and **(F)** IFN-γ and IL-4. Expression data are normalized using *GAPDH* as control gene. ^∗^*P* \< 0.05 and ^∗∗^*P* \< 0.01 were considered statistically significant, respectively.](fmicb-10-02155-g005){#F5}

*A. muciniphila* and Its EVs Regulated Inflammation and Energy Homeostasis in the Colon of Obese Mice {#S3.SS7}
-----------------------------------------------------------------------------------------------------

High-fat diet seems to cause disruption of the intestinal barrier and consequently leads to inflammation. Therefore, the anti-inflammatory effect of *A. muciniphila* and its EVs by TLRs was evaluated in HFD-induced mice. After EV administration, the expression of *TLR-4* reduced more in obese mice when compared with this bacterium ([Figure 4F](#F4){ref-type="fig"}). In comparison with *A*. *muciniphila*, EVs induced significantly lower *TLR-2* expression in both mice's colon ([Figure 4G](#F4){ref-type="fig"}). In the Caco-2 cell line, this bacterium did not stimulate *TLR-4* while it induced *TLR-2* expression. Similar to *in vivo*, EVs induced upregulation in expression of *TLR-2* and downregulation in expression of *TLR-4* in the cell line ([Figure 5B](#F5){ref-type="fig"}). Both this bacterium and EVs induced intestinal immune homeostasis through regulated ratio of pro- and anti-inflammatory cytokine expression in obese mice's colon ([Figures 4H,I](#F4){ref-type="fig"}). In normal mice, a slight increase of pro-inflammatory cytokine *TNF-*α expression was observed after being gavaged by the bacterium ([Figure 4H](#F4){ref-type="fig"}). Conversely, the EVs downregulated significantly the expression of this cytokine. Also, significant anti-inflammatory cytokine *IL-10* upregulation was seen after both administration in normal mice ([Figure 4I](#F4){ref-type="fig"}). *A*. *muciniphila* and its EVs induced both pro- and anti-inflammatory cytokine secretion, while EVs induced significantly lower levels of IL-8 and the levels of IL-4 increased compared with *A*. *muciniphila* in the Caco-2 cell line ([Figures 5D,F](#F5){ref-type="fig"}). *A*. *muciniphila* had a significant effect on an increase in the level of IL-10, compared to EVs ([Figure 5E](#F5){ref-type="fig"}). In addition, the increase in TNF-α level following both treatments was not significant ([Figure 5E](#F5){ref-type="fig"}). Both treatments significantly reduced the level of IFN-γ in comparison with the control group ([Figure 5F](#F5){ref-type="fig"}).

To investigate the role of *A. muciniphila* and its EVs on fat storage, gene expression of Angiopoietin-like 4 (ANGPTL4), which plays a key role in regulatory pathways involving energy and lipid metabolism under HFD, was evaluated in colon of mice. Treatment of *A. muciniphila* and its EVs influences improvement of lipid and energy metabolism in obese mice. These observations were accompanied by increased expression of intestinal ANGPTL4 expression in mice treated with this bacterium ([Figure 4J](#F4){ref-type="fig"}). Moreover, administration of EVs showed slight effects on ANGPTL4 expression in obese mice ([Figure 4J](#F4){ref-type="fig"}). Additionally, treatment with *A. muciniphila* in normal mice induced a high mRNA level of ANGPTL4 in the colon ([Figure 4J](#F4){ref-type="fig"}), whereas EVs were not effective in Angptl4 upregulation, similar to the *in vitro* study ([Figure 5C](#F5){ref-type="fig"}).

Discussion {#S4}
==========

Obesity is characterized by weight gain, fat accumulation, disruption of metabolic and energy homeostasis, and low-grade inflammation ([@B16]; [@B69]). Multiple studies have confirmed the effects of probiotics on obesity, as they improve metabolic parameters and reduce body weight by changing the microbiota composition ([@B58]; [@B20]). Recent evidences show that OMV-released probiotic and commensal bacteria can internalize intestinal epithelial cells and play a crucial role in the modulation of various pathways ([@B5]; [@B11]; [@B25]). Our findings showed that *A. muciniphila*-derived EVs alleviated more body and fat weight gain in obese mice after 5 weeks, compared to the bacterium. Both treatments had effects on the weight of normal mice, while the bacterium had greater effects on EAT weight. In addition, blood glucose and cholesterol levels reduced following treatment with EVs in obese mice.

In comparison with the control group, administration of *A. muciniphila* induced significantly lower levels of glucose and TG in obese mice. In normal mice, the bacterium had more significant effects on TG, compared with EVs. These results may indicate the potential role of the bacterium and its EVs in obesity treatment. Similarly, a recent study revealed that the abundance of *A. muciniphila* decreased in HFD-fed mice, which is strongly correlated with weight gain, increased inflammation, increased expression of lipid-metabolism genes in adipose tissues, and increased level of blood markers (e.g., lipid and glucose) in obese mice ([@B58]). Accumulating evidence shows that probiotic administration leads to a reduction in body weight gain, adipose weight, and obesity biomarkers (e.g., glucose and plasma lipid) in HFD-fed mice ([@B55]; [@B50]). In addition, the effect of probiotics on the improvement of metabolism was confirmed in normal mice ([@B73]).

Several studies indicate that HFD induces an increase in adipocyte size, macrophage infiltration, and secretion of inflammatory mediators associated with obesity pathogenesis ([@B9]). Our meta-analysis, consistent with previous studies, showed that the levels of PPAR-γ and PPAR-α decreased due to obesity, while TGF-β level and inflammation increased in adipose tissues. PPARs, as lipid sensors, regulate the host metabolism by affecting the genes involved in fat storage and energy homeostasis and modulate inflammatory responses; accordingly, they are regarded as the link between lipid signaling and inflammation ([@B68]). Previous findings suggest that PPAR-γ contributes to the regulation of FA metabolism and alleviation of inflammation and fibrosis ([@B33]). Moreover, increased activation of PPAR-α in adipocytes induces FA oxidation, decreases food intake, increases energy expenditure, and regulates inflammatory responses ([@B30]; [@B4]; [@B32]). A recent study revealed that activation of both PPAR-α and PPAR-γ by synthetic agonists might have greater effects on inflammation and obesity amelioration ([@B28]). Our findings showed that administration of *A. muciniphila* and its EVs triggers an increase in PPAR-α and PPAR-γ mRNA content of EAT in both groups, which is indicative of their influence on FA oxidation and energy metabolism. Notably, EVs had a greater effect on the expression of PPARs in EAT in comparison to the bacterium.

In a previous study, administration of *Lactobacillus gasseri* BNR17 showed that alleviation of white adipose tissue weight gain increases FA oxidation by changing *PPAR-*α expression ([@B38]). An increase in the level of TGF-β in adipose tissues influences the production of inflammatory mediators, regulation of energy homeostasis, fat mass expansion, and promotion of collagen deposition, which are associated with obesity in animals and humans ([@B57]; [@B26]; [@B45]; [@B70]; [@B61]). [@B70] showed that neutralization of TGF-β with antibodies has protective effects on diabetes and obesity by improving metabolism. We found that HFD causes an increase in *TGF-*β mRNA content of EAT, compared with the normal diet; in fact, the mRNA level decreased after both administrations in mice. These findings may indicate the potential effect of this bacterium and its EVs on regulating energy metabolism and counteracting obesity.

A large number of studies have reported a correlation between obesity amelioration and PPARs, which directly affect the reduction of inflammatory cytokines or indirectly influence lipid metabolism in adipose tissues ([@B62]; [@B68]). PPAR-α and PPAR-γ are capable of reducing the expression of pro-inflammatory cytokines through influencing adipose size and reversing macrophage infiltration, respectively ([@B65]; [@B62]). On the other hand, activation of TLR-4 in adipose tissues occurs through interactions with gut microbiota LPS or adipocyte lipolysis-released free fatty acids, which can induce the secretion of inflammatory adipocytokines (i.e., IL-6 and TNF) in obesity ([@B12]; [@B32]).

Besides the impact on PPARs, we found that EVs have more significant anti-inflammatory effects on the EAT of obese mice, compared with the bacterium itself. These effects are accompanied by a decrease in the expression of *TLR-4* and pro-inflammatory cytokines, *TNF-*α and *IL-6*, in EAT.

In addition, both treatments had positive effects on normal mice. Several animal studies have shown that probiotic treatments downregulate pro-inflammatory cytokine genes and upregulate the expression of FA oxidation-related genes in white adipose tissues ([@B48]; [@B52]). Collectively, our results showed that both treatments could ameliorate obesity and reverse the obesity effects. These results possibly represent that nano-sized EVs can enter the bloodstream and access other tissues such as adipose tissue as well as regulate a variety of cellular and molecular pathways.

Correlation of dysbiosis with obesity is indicated in several animal and human studies ([@B13]; [@B6]; [@B66]; [@B27]; [@B58]). It is known that obesity increases intestinal permeability, caused by switching of tight junction proteins ([@B39]). Therefore, the level of these proteins such as zonula occludens-1 (ZO-1), occludin (OCLDN), and claudin-1 (CLDN-1) reduces, while *CLDN-2* expression in permeable epithelial cell increases ([@B24]; [@B1]). Our findings showed that HFD-induced colon barrier dysfunction improves significantly after administration of EVs by switching tight junction protein expression in obese mice. Moreover, *A. muciniphila* and its EVs upregulated the expression of tight junction proteins not only in Caco-2 cells, but also in mice.

Additionally, we found a significant increase in *CLDN-2* expression among HFD-fed mice, while EVs had a considerable effect on *CLDN-2* downregulation in obese mice. In this regard, a previous study showed that *A. muciniphila* could regulate tight junction protein expression and strengthen the intestinal barrier in obese mice by affecting *TLR-2* expression ([@B51]). [@B15] demonstrated weight loss in HFD-fed mice after treatment with *A. muciniphila*-derived EVs, which also diminished the HFD-induced gut permeability. Moreover, a recent study showed that *A. muciniphila* EVs have more beneficial effects on the mucosal integrity and weight gain of colitis mice, compared with the bacterium ([@B37]). Other animal studies have shown that oral administration of probiotics improves the gut barrier integrity and metabolic disorders ([@B24]; [@B51]; [@B41]). In line with the abovementioned findings, we showed that probiotics and their bioactive factors reinforce the epithelial barrier integrity through upregulation of several tight junction-related genes. An increase in the gut permeability stimulates the immune cells in the lamina propria by pathogenic and beneficial bacteria (i.e., LPS) and ultimately leads to inflammation. Probiotic, as a potential therapeutic option to target obesity, interacts with TLRs on intestinal epithelial or immune cells and stimulates the secretion of various cytokines in the gut, ultimately leading to mucosal immune homeostasis ([@B67]).

Since *Akkermansia muciniphila* is closer to the host epithelial cells, it exhibits significant immune regulatory responses. In our study, the cell line, after exposure to *A. muciniphila*, showed activated cells expressing *TLR-2*, but no change in *TLR-4* expression was found, similar to normal mice. Generally, TLR-4 is the best marker for identifying Gram-negative LPS, while commensal bacterial LPS are different from pathogenic bacteria, which stimulate TLR-2 instead of TLR-4 and cause immune system tolerance ([@B3]). In this regard, an *in vitro* study, comparing the effects of *A. muciniphila* with *E. coli* LPS on HT29 cells, showed that *A. muciniphila* LPS are distinct from *E. coli* LPS ([@B56]). Conversely, another study demonstrated that *A. muciniphila* is a strong inducer of TLR-4 activation in HEK-Blue cells ([@B49]). Differences in TLR-4 stimulation may be due to variations in cell type and culture medium.

Recent studies have revealed that gut microbiota possibly communicates with the host by secreting EVs and mediates immune signaling pathways by interacting with TLRs ([@B59]; [@B25]). Our findings showed that treatment with *A. muciniphila*-derived EVs activated *TLR-2* expression, while reducing TLR-4 expression in the cell line and mice. In the present study, treatment with *A. muciniphila* in obese mice induced *TLR-2* upregulation and *TLR-4* downregulation. We found that the bacterium induces higher levels of pro-inflammatory cytokines in the cell line, compared with EVs. Similarly, another study on the same cell line showed that *A. muciniphila* stimulates IL-8 secretion, and the concentration of IL-8 was significantly lower than that reported in *E. coli* treatment ([@B56]). Moreover, another study reported that *A. muciniphila* EVs induce IL-6 secretion in CT26 cells. However, before treatment with *E. coli*-derived EVs, pretreatment with *A. muciniphila* EVs indicated the anti-inflammatory effects of these EVs ([@B37]). Previous studies show that probiotics can modulate immune homeostasis by inducing pro- and anti-inflammatory cytokines in the cell line ([@B49]; [@B53]). Following the administration of *A. muciniphila* in our study, high expression levels of pro-, and anti-inflammatory cytokines were observed in comparison with EV treatment in normal mice. These observations, which are in line with recent research, may show that induction of pro-inflammatory cytokine secretion by this bacterium in a normal intestine can play a key role in the immune system preparation for confronting bacterial pathogens and developing intestinal tolerance to commensal microbiota ([@B49]).

On the other hand, gavage of obese mice with *A. muciniphila* and its EVs showed that both treatments could ameliorate intestinal inflammation. In addition, both *A. muciniphila* and its EVs induced anti-inflammatory cytokine expression in obese mice by affecting TLR-2 activation. Multiple studies have demonstrated that probiotics can ameliorate inflammation, caused by TLR-2-dependent induction of IL-10 secretion ([@B47]; [@B35]; [@B36]). Overall, our findings, in line with previous studies, revealed the anti-inflammatory properties of *A. muciniphila* and its secretory vesicles in inflammatory diseases, especially obesity.

The gut microbiota can influence the energy balance, as well as weight control in the host through various mechanisms, including intestinal ANGPTL4, which diminishes lipogenesis, fat storage, and finally energy balance in the host ([@B34]; [@B63]). Moreover, it increases the plasma TG level and reduces inflammation ([@B29]). Angptl4 is considered a link between the gut microbiota and obesity, preventing FA-induced inflammation ([@B44]). Since *ANGPTL4* expression reduces in obesity, use of probiotics for *ANGPTL4* upregulation may be the main target of HFD-induced obesity prevention or treatment ([@B71]). In the current study, *A. muciniphila* induced the upregulation of *ANGPTL4* expression in both Caco-2 cell line and mice. A recent study also revealed that *A. muciniphila* metabolites, such as propionate, regulate *ANGPTL4* expression in intestinal organoids, and modulate lipid metabolism ([@B46]). Moreover, comparison of ANGPTL4 knockout (ANGPTL4^--/--^) and wild-type mice in an *in vivo* study showed that ANGPTL4^--/--^ mice do not counteract HFD-induced weight gain due to increased LPL activity ([@B7]). In the present study, we found that bacterium-derived EVs are not effective in Angptl4 upregulation in the cell line and normal mice, which is in contrast with the slight change in Angptl4 expression in obese mice. Regarding *ANGPTL4* expression, it has been reported that treatment with live *Lactobacillus rhamnosus* CNCMI-4317 upregulates Angptl4 expression in HT29 cells, whereas the heat-inactivated bacterium and its supernatant do not affect Angptl4 regulation ([@B34]).

Our findings, in line with previous research, reveal that live probiotics probably affect the intestinal Angptl4 upregulation *via* surface molecules and prevent obesity ([@B34]). Moreover, the minor effect of EVs on the regulation of intestinal Angptl4 expression could be attributed to surface-exposed molecules in obese mice. These observations support the hypothesis that inflammation of the intestine, as the first site affected by HFD, can induce adipose inflammation and contribute to the progression of obesity ([@B39]). Therefore, early detection of intestinal inflammation and amelioration *via* probiotic treatment may have beneficial effects on the prevention of obesity.

In summary, HFD consumption can influence dysbiosis, inflammation, permeability of the mucosal barrier, accumulation of fat, and weight gain, and consequently lead to obesity. It was revealed that *A. muciniphila* and administration of its EVs could reverse adverse effects of obesity in obese mice ([Figure 6](#F6){ref-type="fig"}). In fact, *A. muciniphila*-derived EVs showed more significant effects on adipose dysfunction, inflammation reduction, alleviation of intestinal permeability, and reversal of obesity effects compared to this bacterium. Therefore, these EVs may be considered as a possible target of HFD-induced obesity prevention or treatment. Finally, regarding the distinct effects of EV--host interaction on the treatment of obesity, further research is necessary to corroborate our findings.

![Administration of *A. muciniphila* and its EVs improves the intestinal and metabolic homeostasis in obese mice. Obesity is associated with the disruption of the intestinal barrier integrity, inflammation, and fat mass gain (left). Oral administration of *A. muciniphila* or its EVs increase the expression of tight junction proteins and *TLR-2* and reduce the expression of *TLR-4* and pro-inflammatory cytokines in the colon of obese mice (right). Also, treatment with *A. muciniphila* and its EVs affects FA oxidation, local inflammation genes, and fat-mass loss in the EAT of obese mice. HFD, high-fat diet; EVs, extracellular vesicles; *TLR*, toll-like receptor; LPS, lipopolysaccharide; PPAR, peroxisome proliferator-activated receptor; Zo-1, zonula occludens-1; Ocldn, occludin; Cldn, claudin; Angptl4, angiopoietin-like 4; TNF-α, tumor necrosis factor-α; IL-10, interleukin-10; TGF-β, transforming growth factor-β; and Glc, glucose.](fmicb-10-02155-g006){#F6}

Conclusion {#S5}
==========

Despite molecular interactions between the intestinal microbiota, host energy balance, and inflammation, some obesity and clinical studies show that manipulation of gastrointestinal microbiota with probiotics can promote the pathophysiology of obesity. Our results indicated the crucial role of *A. muciniphila* and its EVs in health promotion and obesity treatment. Based on our findings and the leaky-gut hypothesis, *A. muciniphila*-derived EVs can be considered as more appropriate targets in new therapeutic strategies for obesity.
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